[go: up one dir, main page]

WO2025057207A1 - Compositions laxatives - Google Patents

Compositions laxatives Download PDF

Info

Publication number
WO2025057207A1
WO2025057207A1 PCT/IN2024/051716 IN2024051716W WO2025057207A1 WO 2025057207 A1 WO2025057207 A1 WO 2025057207A1 IN 2024051716 W IN2024051716 W IN 2024051716W WO 2025057207 A1 WO2025057207 A1 WO 2025057207A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
lactitol
flaxseed
constipation
laxative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IN2024/051716
Other languages
English (en)
Inventor
Venkat Ramana Naidu
Alok Ranjan SAMAL
Uma Sowjanya Asapu
Venugopal Hariharan
Anup Avijit Choudhury
Pradip Kumar Sasmal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of WO2025057207A1 publication Critical patent/WO2025057207A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum

Definitions

  • the present invention relates to compositions, e.g., formulations or preparations for treating, ameliorating or preventing chronic idiopathic constipation.
  • compositions comprising a combination of sugar alcohols, preferably Lactitol, and Flaxseed, for treating, ameliorating or preventing chronic idiopathic constipation.
  • the human intestinal microbiota or the gastrointestinal (GI) microbiota is a collection of around 3.3 million microorganisms that live within the gastrointestinal tract.
  • Majority of the GI microbiota is obligate bacteria e.g. Lactobacillus, Bifidobacterium, and Bacteroides spp.), performs many important health-promoting functions, for example, aiding digestion of important nutrients.
  • Minority of GI microbiota is potentially pathogenic (e.g. Pseudomonas aeruginosa and Campylobacter jejuni) and plays a vital role in the pathogenesis of various diseases.
  • Constipation is a common gastrointestinal disorder which affects about 28% of the population. This problem is mainly encountered in adults and paediatric patients and can generate considerable suffering for patients due to both the unpleasant physical symptoms and psychological preoccupations that can arise. Constipation occurs when bowel movements become less frequent and stools become difficult to pass. It happens most often due to changes in diet or routine, or due to inadequate intake of fiber. Constipation may be acute or chronic with the latter usually being defined as a duration of greater than three months. Acute constipation begins suddenly and noticeably.
  • Chronic Idiopathic Constipation and Irritable Bowel Syndrome both present as chronic constipation and are distinct from acute constipation.
  • Chronic Idiopathic Constipation is a bowel disorder, defined as a state of unsatisfactory defecation characterized by infrequent stools and difficulty in passing stools, or both.
  • Chronic Idiopathic Constipation is without any known cause or identified underlying illness.
  • Diagnosing of constipation includes Physical examination, Abdominal X-ray, Lower GI (gastrointestinal) series (also called barium enema), Colonoscopy, Sigmoidoscopy, Colorectal transit study, Anorectal function tests, anorectal manometry, defecography, balloon explusion test, MRI defecography.
  • Constipation usually begins with diet and lifestyle changes like physical activity, a high-fiber diet, adequate intake of fluids followed by medications like laxatives.
  • Laxatives available as over-the-counter:
  • Fiber supplements adds bulk to the stool thereby making them softer and easier to pass.
  • Stimulants causes contractions in intestine.
  • Osmotic laxatives increases secretion of fluid from the intestines and helps to stimulate bowel movements, thereby helps stool move through the colon.
  • Lactitol Oral magnesium hydroxide, Magnesium citrate, Lactulose
  • Lubricants such as mineral oil enable stool to move through your colon more easily.
  • Stool softeners Stool softeners moisten the stool by drawing water from the intestines
  • Enemas and suppositories Enemas soften stools and produce bowel movement. Suppositories aid in moving stool out of the body by providing lubrication and stimulation.
  • Osmotic Laxatives are widely used in the treatment of Chronic Idiopathic constipation (CIC). Osmotic laxatives alter the balance of fluid with substances such as salts, sugars, and other organic compounds that encourage the movement of water into the lumen. There are several osmotic laxatives used for the treatment of constipation.
  • Disaccharide sugar is widely prescribed osmotic laxative in India.
  • Lactulose is a disaccharide sugar with osmotic effect and Lactitol is its analog.
  • Lactulose is a nonabsorbable synthetic disaccharide that consists of galactose and fructose linked by a bond resistant to lactase. Both Lactulose and its analog Lactitol are widely used and well tolerated Laxatives.
  • Lactitol is a sugar alcohol, an analog of Lactulose. Chemically, Lactitol is 4-0-a-D- Galactopyranosyl-D-glucitol with the following structure.
  • Lactitol is available as oral solution and marketed as Pizensy® since 2020 in the United States for the treatment of chronic idiopathic constipation (CIC) in adults.
  • CIC chronic idiopathic constipation
  • Lactitol is an osmotic laxative that exerts its pharmacologic effect by creating a hyperosmotic environment within the small intestine.
  • the osmotic effect generated by Lactitol draws water into the small intestine, which loosens stools and ultimately facilitates bowel movements. It is a non- digestible sugar and reaches the intestine in unchanged manner and recalls the water in an osmotic matter and by fermentation it increases the faeces volume and reduce the permanence time in colon. These conditions are related to each other and facilitates the defecation. Therefore, Lactitol is well tolerated by patients and is able to increase the evacuation frequency and faeces consistency and useful in treating chronic constipation.
  • Lactitol over lactulose due to comparable efficacy and tolerability, better palatability and taste when compared with lactulose which increases patient compliance. Lactitol could be used in diabetic patients as well due to its low glycemic index and hence no effect on glucose and insulin levels. Lactitol is proven to be safe and effective to use at a dosage of 10g per day.
  • Lactitol have common side effects such as upper respiratory tract infections, flatulence, diarrhea, abdominal distension, dyspepsia, cramps and increased blood creatinine phosphokinase.
  • most common side effect is flatulence.
  • Lactitol when combined with flaxseed has synergistically effective action. Also, this combination has very fewer side effects, improved stool frequency and better consistency when compared with Lactitol compositions.
  • Flaxseed is a seed from the flax plant, one of several species of the plant genus Linum, containing omega-3 fatty acids and alphalinolenic acid. Flaxseeds are packed with nutrients like protein, potassium, magnesium, protein, and fiber. Flaxseed-derived foods, lignans, and essential fatty acids possess anti-inflammatory, antioxidant, lipid-lowering, and antineoplastic properties.
  • Flaxseeds contain a good mix of both soluble and insoluble fiber, which helps reduce intestinal transit time and adds bulk to stools. They have natural laxative properties and are used to treat constipation by increasing bowel frequency. 1 to 4 tablespoons of flaxseed as a whole or taken as oil or in a glass of water taken regularly to relieve constipation. Flaxseed is proven to be safe to use in the treatment of constipation.
  • Lactitol and Flaxseed showed a synergistic effect in treating chronic constipation and also showed a significant decrease in side effects, especially flatulence, when compared to formulations containing only Lactitol. Lactitol and Flaxseed combination also showed improvement in stool frequency and consistency in the treatment of chronic idiopathic constipation.
  • composition comprising a combination of Lactitol and Flaxseed.
  • An object of the present invention is to provide a composition containing combination of Lactitol and Flaxseed, useful for the treatment of chronic idiopathic constipation.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) an osmotic laxative, and b) a natural laxative wherein the pharmaceutical composition is selected from oral solution, powder and granules.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) an osmotic laxative selected from sugar alcohol and b) a natural laxative
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) sugar alcohol selected from Lactitol, Mannitol, Erythritol, Sorbitol, Xylitol or combinations thereof and b) a natural laxative selected from flaxseed, chia seed, prune, castor oil
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) Lactitol, and b) Flaxseed.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) Lactitol, and b) Flaxseed and further comprising a pharmaceutically acceptable carrier which is selected from diluent, humectant, lubricant, viscosifier, acidifying agent, alkalinizing agent, preservative, flavoring agent and sweetening agent.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) Lactitol, b) Flaxseed, and c) a pharmaceutically acceptable carrier wherein the pharmaceutical composition is preferably oral solution.
  • the present specification relates to a pharmaceutical composition comprising combination of a) 5g of Lactitol, b) 5g of Flaxseed extract, and c) a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is preferably oral solution.
  • the present specification relates to a pharmaceutical composition comprising combination of a) 5g of Lactitol, b) 2.5g of Flaxseed extract, and c) a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is preferably oral solution.
  • the present specification relates to a pharmaceutical composition, wherein a combination of Lactitol and Flaxseed are provided in synergistically effective amounts for use in the treatment of constipation, wherein the constipation is chronic idiopathic constipation.
  • the present specification relates to a pharmaceutical composition, wherein a combination of Lactitol and Flaxseed are provided in synergistically effective amounts for use in the treatment of chronic idiopathic constipation in patients who experiences an average of fewer than 3 bowel movements per week for more than 3 months.
  • composition of Lactitol and Flaxseed of the present specification can be used for the treatment of chronic idiopathic constipation in subjects with less adverse effects compared to formulations comprising only Lactitol.
  • This invention relates to a formulation comprising combination of Lactitol and Flaxseed, for the treatment of chronic idiopathic constipation, and to improve stool frequency and consistency, with lesser side -effects when compared with compositions comprising only Lactitol.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) an osmotic laxative, and b) a natural laxative wherein the pharmaceutical composition is selected from oral solution, powder and granules.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) an osmotic laxative selected from sugar alcohol and b) a natural laxative
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) sugar alcohol selected from Lactitol, Mannitol, Erythritol, Sorbitol, Xylitol or combinations thereof and b) a natural laxative selected from flaxseed, chia seed, prune, castor oil
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) Lactitol and b) Flaxseed.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) Lactitol, and b) Flaxseed and further comprising a pharmaceutically acceptable carrier which is selected from diluent, humectant, lubricant, viscosifier, acidifying agent, alkalinizing agent, preservative, flavoring agent and sweetening agent.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) Lactitol, b) Flaxseed, and c) a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is preferably oral solution.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of a) 5g of Lactitol, b) 2.5g of Flaxseed extract, and c) a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is preferably oral solution.
  • the present specification relates to a pharmaceutical composition, wherein a combination of Lactitol and Flaxseed are provided in synergistically effective amounts for use in the treatment of constipation, wherein the constipation is chronic idiopathic constipation.
  • the present specification relates to a pharmaceutical composition, wherein a combination of Lactitol and Flaxseed are provided in synergistically effective amounts for use in the treatment of chronic idiopathic constipation in patients who experiences an average of fewer than three bowel movements per week for more than 3 months.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of Lactitol and Flaxseed, wherein Lactitol and Flaxseed independently present in an amount between 15 to 60 % with respect to total weight of composition.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of Lactitol and Flaxseed, wherein Lactitol and Flaxseed independently present in an amount between 25 to 50% with respect to total weight of composition.
  • the present specification relates to a pharmaceutical composition
  • a pharmaceutical composition comprising combination of Flaxseed and Lactitol in a ratio from 1:0.1 to 0.1:10 respectively.
  • the dose of lactitol is in an amount of 0.2 g to 20g/ day.
  • the dose of flaxseed extract is 2 g/ day, 2.5 g/day, 3 g/day. 3.5 g/day, 4 g/day, 4.5 g/day, 5 g/day, 6 g/day, 7 g/day, 8 g/day, 9 g/day, 10 g/day, 11 g/day, 12 g/day, 13 g/day, 14 g/day, 15 g/day, 16 g/day, 17 g/day, 18 g/day, 19 g/day, 20 g/day.
  • compositions of the present invention are also useful in the treatment and/or management of diseases or disorders of the bowel primarily associated with constipation, diarrhea or indigestion.
  • compositions refers to oral dosage forms preferably in the form of Oral solution, Granules, Syrup, Powder, Sachet and the like. These dosage forms are generally prepared by using one or more suitable pharmaceutically acceptable excipients.
  • composition or formulation are used herein interchangeably.
  • laxative refers to an active agent which is having a tendency to loosen or relax, specifically producing bowel movements and relieving constipation. Any substance that stimulates evacuation of faeces.
  • Frlaxseed or “Flaxseed Extract” or “Flaxseed Mucilage” can be used interchangeably.
  • osmotic refers to the concentration of a solute when two solutions are separated by a membrane (which is permeable to solvents) that selectively blocks the passage of solute molecules. Any substance that facilitates the passage of solvent from a low solution to a high solute concentration solution.
  • constipation refers to a condition in which a subject suffers from infrequent bowel movements or painful and / or difficult to pass bowel movements. Subjects who experience constipation often suffer from a feeling of strain during defecation and / or incomplete defecation following defecation. In some embodiments, constipation refers to a subject who experiences an average of fewer than 3 bowel movements per week, where " bowel movement" is the passage and elimination of feces.
  • chronic refers to a long-lasting condition.
  • chronic can refer to a condition that lasts at least 1, 2, 3, or 4 weeks.
  • chronic can also refer to a condition lasting at least 1, 2, 3, 4, 5 or 6 months.
  • the subject is receiving laxative to reduce chronic idiopathic constipation that persisted for atleast 3 months.
  • subject refers to mammals, humans as well as domesticated animals (e.g. horses, dogs, cats, etc.) and laboratory animals (e.g. mice, rats, dogs, chimpanzees, monkeys) Etc.) and other animal subjects.
  • the subject is a human.
  • combination is intended to refer to therapy by any route of administration in which two or more active agents are administered together to a subject.
  • the active substances can be in the same dosage formulation or in different formulations.
  • the combination therapy is administering two active agents in a single dosage form.
  • Flaxseed may be in the form of milled or unmilled seeds or fractions thereof and can be used as starting material.
  • the outer part of flaxseed consists of a water-soluble mucilage i.e., the epidermic layer.
  • Under the mucilage there is the actual husk substance consisting of three layers, i.e., spermoderm, endosperm, and cotyledon from outermost to innermost.
  • the outer husk surface is spermoderm layer which contains mucilage and lignans.
  • the inner husk surface is the endosperm, and the seed core consists of the cotyledon, which accounts for about half of the weight of the seed.
  • the flaxseed of the present invention is in the form of husk or mucilage, preferably mucilage.
  • suitable diluents include, but not limited to the group consisting of different grades of starches, such as maize starch, potato starch, rice starch, wheat starch, pregelatinised starch, fully pregelatinised starch; cellulose derivatives, such as microcrystalline cellulose or silicified microcrystalline cellulose; sugar alcohols such as mannitol, erythritol, sorbitol, xylitol; monosaccharides like glucose; oligosaccharides like sucrose and lactose such as lactose monohydrate, lactose anhydrous, spray dried lactose or anhydrous lactose; calcium salts, such as calcium hydrogen phosphate; particularly preferably the fillers are selected from the group consisting of, mannitol, sorbitol, xylitol and the like. More preferably the diluent is Mannitol.
  • humectants include, but not limited to the group consisting of sorbitol, mannitol, glycerol, propylene glycol, glycerin agar, calcium carbonate, potato starch, tapioca starch, alginic acid, certain silicates, colloidal silicon dioxide, sodium starch glycolate; particularly preferably the humectant is glycerin and the like.
  • glycerin is present in an amount of from 5 to 15%.
  • glycerin is present in an amount of from 8 to 12% by weight of formulation.
  • suitable lubricants include, but not limited to the group consisting of sodium chloride, stearic acid, talc, glyceryl behenate, sodium stearyl fumarate and magnesium stearate; particularly preferably the lubricant is sodium chloride and the like.
  • sodium chloride is present in an amount of from 0.1 to 3%.
  • sodium chloride is present in an amount of from 0.5 to 1.5% by weight of formulation.
  • suitable viscosifiers or thickeners include, but not limited to the group consisting of starch, guar gum, Gellan gum, xanthan gum, sodium carboxymethyl cellulose, HPMC, HPC, Sodium CMC.
  • sodium carboxymethyl cellulose is present in an amount of from 0.1 to 1.5%.
  • sodium carboxymethyl cellulose is present in an amount of from 0.3 to 1% by weight of formulation.
  • Suitable anti-oxidants include, but not limited to BHT, Tocopherol acetate, Sodium metabisulfite, BHA.
  • Preservatives include, but not limited to the group consisting of sorbic acid and derivatives, sodium benzoate, sodium metabisulphate, Sodium salts of methyl paraben and propyl paraben, benzoic acid, methyl paraben, propyl paraben, sodium benzoate, potassium sorbate, sorbic acid, particularly preferably the preservatives are selected from the group consisting of sodium benzoate, methyl paraben, propyl paraben, sodium methyl paraben, sodium propyl paraben and the like.
  • suitable flavors include, but not limited to the group consisting of Jeera flavor, Strawberry flavor, orange flavor, apple flavor, grape flavor, lemon flavor, banana flavor, cherry flavor, etc.
  • Suitable sweeteners may be selected from, but not limited to the group consisting of sorbitol, sucrose, aspartame, sucralose, saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin; particularly preferably the sweeteners are selected from the group consisting of sorbitol, sucrose, sucralose, saccharin sodium and the like.
  • sweetener is present in an amount of from 0.005 to 0.5%.
  • sweetener is present in an amount of from 0.01 to 0.1% by weight of formulation.
  • Composition may contain acidifying and alkalinizing agent.
  • Acidifying agents can be selected from, but not limited to citric acid, succinic acid, fumaric acid, malic acid, maleic acid, glutaric acid, lactic acid and mixtures thereof and the like.
  • Alkalizing agent can be selected from, but not limited to magnesium oxide, aluminium oxide, ammonium hydroxide, magaldrate, an alkali metal salt or alkaline earth metal salt, such as sodium bicarbonate, calcium carbonate or sodium citrate, sodium dihydrogen phosphate, Disodium hydrogen phosphate, an alkali metal hydroxide such as sodium hydroxide, potassium hydroxide or lithium hydroxide, or an alkaline earth metal hydroxide such as calcium hydroxide or magnesium hydroxide, with magnesium oxide or calcium carbonate and meglumine and the like.
  • the preferred composition of the present invention is liquid or solid composition for oral use, even more preferably an aqueous oral solution, powder sachet, granules.
  • the composition of the present invention contains Lactitol and Flaxseed.
  • the composition according to the present invention can be a medicament, a medicated food, a pharmaceutical composition or a food supplement.
  • compositions of the present invention containing combination of Lactitol and Flaxseed are particularly effective in the treatment of constipation allowing increase in the weight of faeces and consistency and overall reduction in adverse effects when compared with Lactitol compositions.
  • step 1 To required quantity of water, glycerin was added and heated upto 60°C. Preservatives were added 2. To step 1, Lactitol was added and stirred well until clear solution was formed.
  • Flaxseed mucilage was added to above step and homogenised to form clear solution. 6. Finally, flavour was added followed by weight make up and stirring to form clear solution.
  • step 1 To required quantity of water, glycerin was added and heated upto 60°C. Preservatives were added 2. To step 1, Lactitol was added and stirred well until clear solution was formed.
  • Flaxseed extract was added to above step and homogenised to form clear solution, (for examples 2d- 2g)
  • flavour was added followed by weight make up and stirring to form clear solution.
  • step 1 Lactitol was added and stirred well until clear solution was formed.
  • Flaxseed extract was added to above step and homogenised to form clear solution.
  • flavour was added followed by weight make up and stirring to form clear solution.
  • step 1 Lactitol was added and stirred well until clear solution was formed.
  • Flaxseed mucilage was added to above step and homogenized to form clear solution. Finally, flavor/flavor modulator was added followed by weight make up and stirring to form clear solution.
  • step 1 Lactitol was added and stirred well until clear solution was formed.
  • Flaxseed mucilage was added to above step and homogenized to form clear solution. Finally, flavor/flavor modulator was added followed by weight make up and stirring to form clear solution.
  • the objective of the study was to evaluate the laxative effects (along with reduction in flatulence/ bloating) of standalone Lactitol and combination of flaxseed mucilage with Lactitol at different concentrations, on rats with loperamide -induced constipation.
  • the evaluation parameters were i) faecal score (visual appearance), ii) faecal count iii) faecal weight and iv) % moisture content.
  • Table- 1 below represents the study result data.
  • Constipation Induction Period 5 days before starting the treatment and during treatment
  • LT Lactitol
  • SM Flaxseed Mucilage
  • the objective of the study was to evaluate the laxative effects of various Combinations of Flax Seed Mucilage and Lactitol in different concentrations, on rats with loperamide-induced constipation.
  • the evaluation parameters were i) faecal score (visual appearance), ii) faecal count iii) faecal weight and iv) Intestinal Transit Ratio.
  • Table-2 below represents the study result data. Results are depicted in figures 1 to 4 for the evaluation parameters
  • Constipation Induction Period 5 days before starting the treatment and during treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition comprenant un laxatif osmotique, et un laxatif naturel. La présente invention concerne une composition comprenant une combinaison d'un laxatif osmotique choisi parmi un alcool de sucre et un laxatif naturel. La présente invention concerne une composition comprenant une combinaison d'alcool de sucre choisi dans le groupe constitué par le lactitol, le mannitol, l'érythritol, le sorbitol, le xylitol ou des combinaisons de ceux-ci et un laxatif naturel choisi parmi les graines de lin, les graines de chia, les prunes, l'huile de ricin. La présente invention concerne une composition contenant une combinaison d'un alcool de sucre, de préférence du lactitol, et des graines de lin, pour le traitement de la constipation idiopathique chronique. La composition est efficace de manière synergique et aide à réduire les effets secondaires et à améliorer la fréquence et la cohérence des selles chez des patients.
PCT/IN2024/051716 2023-09-13 2024-09-12 Compositions laxatives Pending WO2025057207A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202341061508 2023-09-13
IN202341061508 2023-09-13

Publications (1)

Publication Number Publication Date
WO2025057207A1 true WO2025057207A1 (fr) 2025-03-20

Family

ID=95021700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2024/051716 Pending WO2025057207A1 (fr) 2023-09-13 2024-09-12 Compositions laxatives

Country Status (1)

Country Link
WO (1) WO2025057207A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004292356A (ja) * 2003-03-27 2004-10-21 Rohto Pharmaceut Co Ltd 瀉下用製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004292356A (ja) * 2003-03-27 2004-10-21 Rohto Pharmaceut Co Ltd 瀉下用製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUMAR NEERAJ, KISHORE KAMAL, ROHILKHAND UNIVERSITY M J P: "CHEMICAL AND HERBAL REMEDIES FOR CONSTIPATED PATIENTS", INDIAN JOURNAL OF DRUGS, vol. 1, no. 2, 1 June 2013 (2013-06-01), pages 23 - 37, XP093294503, ISSN: 2348-1684 *

Similar Documents

Publication Publication Date Title
TW200930385A (en) Composition with active ingredient combination for the treatment of constipation
JPH05255097A (ja) 液状組成物
WO2007057924A1 (fr) Composition laxative a base de triphala
JP4113242B1 (ja) 消化器症状の防止剤
CN112089717B (zh) 一种阿拉伯糖的用途和用于肠道准备的组合物
WO2025057207A1 (fr) Compositions laxatives
JP4122371B1 (ja) メニエール病治療薬
JP4081131B1 (ja) メニエール病治療薬
CN111467356B (zh) 含有l-阿拉伯糖的治疗便秘的药物组合物及其应用方法
KR102355499B1 (ko) 배변 개선용 조성물
JP4071818B1 (ja) 甘味料
ES2907081T3 (es) Composición para el tratamiento del estreñimiento
KR20100014346A (ko) 메니에르병 치료약
Widjanarko et al. Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats
ES2863979T3 (es) Composición farmacéutica para el tratamiento del estreñimiento
ES2896702T3 (es) Composición para el tratamiento del estreñimiento
ES2896689T3 (es) Composición para el tratamiento del estreñimiento
RU2773084C2 (ru) Композиция для кратковременного и долговременного лечения запоров
HK40028166A (en) Composition for the treatment of constipation
JP4778108B2 (ja) メニエール病治療薬
JP4676522B6 (ja) メニエール病治療薬
CN111356462A (zh) 用于治疗急性和慢性便秘的组合物
HK40029841A (en) Composition for the acute and chronic treatment of constipation
WO2009116490A1 (fr) Remède pour la maladie de ménière
JP2019043900A (ja) ラクツロースを有効成分とする便秘症治療剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24864913

Country of ref document: EP

Kind code of ref document: A1